Our lead programs, TTI-621 and TTI-622, are SIRPαFc decoy receptors designed to block the CD47 “don’t eat me” signal and activate both the innate and adaptive immune systems. Below please find a list of our current clinical trials.
TTI-621-01 (NCT02663518) is a multicenter, open-label phase 1 trial of intravenously administered TTI-621 in patients with relapsed/refractory hematologic malignancies.
TTI-622-01 (NCT03530683) is a two-part, multicenter, open-label, phase 1a/1b study in patients with advanced relapsed or refractory lymphoma or multiple myeloma.
Trillium Therapeutics Inc.’s Compassionate Use Policy can be found here.
TTI-621-01 (NCT02663518) is a multicenter, open-label phase 1 trial of intravenously administered TTI-621 in patients with relapsed/refractory hematologic malignancies. Thus far, over 200 patients have been treated with doses ranging from 0.05 to 1.4 mg/kg. TTI-621 was generally well tolerated with the most frequent drug related adverse events being low grade infusion reactions and transient thrombocytopenia that was not associated with bleeding. Importantly, monotherapy activity was observed in patients across a range of hematologic malignancies. Further dose escalation, evaluating higher dose levels of TTI-621, is currently in progress in patients with cutaneous T-cell lymphoma.
This study is currently recruiting patients. For more information, including a list of trial locations, please refer to clinicaltrials.gov.
TTI-622-01 (NCT03530683) is a two-part, multicenter, open-label, phase 1a/1b study in patients with advanced relapsed or refractory lymphoma or multiple myeloma. In the phase 1a dose-escalation part, lymphoma patients are being enrolled in sequential dose cohorts to receive TTI-622 once weekly to characterize safety, tolerability, pharmacokinetics, and to determine the maximum tolerated dose. In the phase 1b part, patients with hematologic malignancies will be treated with TTI-622 in combination with other agents. Emerging data from the trial indicates that TTI-622 is well tolerated and exhibits dose dependent drug exposure and target engagement. TTI-622 has also demonstrated some initial monotherapy activity. The trial is ongoing with further dose escalation in progress.
This study is currently recruiting patients. For more information, including a list of trial locations, please refer to clinicaltrials.gov.